Key Insights
Analyst consensus: Seven analysts rate Clene as 'Moderate Buy' with an average price target of $32.60, suggesting potential upside from the current price of $6.11.
Financial performance: Clene reported a quarterly EPS loss of $0.88, missing the consensus estimate of $0.74, with minimal revenue of $0.08 million.
Insider activity: Director David J. Matlin purchased 33,333 shares at $6.50, while insiders sold approximately 293,754 shares in the last 90 days; insiders own 35.30% of the company.
AI Analysis
Clene Inc. is positioned in a high-risk, high-reward scenario. If clinical trials for CNM-Au8 yield positive results and the company secures regulator...
Market Outlook
Short-Term
In the next 1-3 months, Clene's stock may experience volatility due to upcoming clinical trial results and market reactions to financial performance.
Long-Term
Recent News
Continue your research
Keep researching Clene Inc Receives Moderate Buy Rating
Move from the topic summary into related coverage, article-level impact analysis, and the next scheduled catalyst.
Explore market intelligence
Connect this story to current themes across macro, equities, commodities, and risk.
Follow AI financial news
Find related coverage ranked around the assets and market themes you follow.
Analyze a market story
Review sentiment, relevance, likely impact, timeframe, confidence, and uncertainty.
Prepare for market events
Check scheduled catalysts and create event-specific email reminders with optional AI context.
Unlock the full Clene Inc Receives Moderate Buy Rating analysis
Get AI-powered insights, alerts, and market analysis for Clene Inc Receives Moderate Buy Rating and other topics you follow.
No credit card required